Intech Investment Management LLC Invests $307,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Intech Investment Management LLC bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, Holdings Channel reports. The fund bought 36,847 shares of the company’s stock, valued at approximately $307,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Profund Advisors LLC increased its holdings in Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock worth $143,000 after acquiring an additional 1,680 shares in the last quarter. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amneal Pharmaceuticals by 13.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock valued at $222,000 after buying an additional 4,115 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals in the third quarter valued at $37,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Amneal Pharmaceuticals by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock valued at $493,000 after purchasing an additional 5,146 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 17.46% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. Barclays raised their target price on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial raised their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Finally, Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $8.81 on Thursday. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -12.96 and a beta of 1.12. The stock has a 50 day simple moving average of $8.54 and a 200-day simple moving average of $7.82. Amneal Pharmaceuticals, Inc. has a 1-year low of $4.46 and a 1-year high of $9.48.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.